Размер шрифта
Цветовая схема
Изображения
Форма
Межсимвольный интервал
Межстрочный интервал
стандартные настройки
обычная версия сайта
закрыть
  • Вход
  • Регистрация
  • Помощь
Выбрать БД
Простой поискРасширенный поискИстория поисков
Главная / Результаты поиска

Omega-3 long-chain polyunsaturated fatty acids and preeclampsia: Trials say “No,” but is it the final word?

Burchakov D. I., Kuznetsova I. V., Uspenskaya Yu. B.
Nutrients
Vol.9, Issue12, Num.1364
Опубликовано: 2017
Тип ресурса: Обзор

DOI:10.3390/nu9121364

Аннотация:
Preeclampsia is a dangerous disorder of pregnancy, defined as hypertension with proteinuria. Its nature remains elusive, and measures of prevention and treatment are limited. Observational studies have suggested that preeclampsia is associated with low intake of omega-3 long-chain polyunsaturated fatty acids (LCPUFA). In recent decades, researchers studied LCPUFA supplementation as a measure to prevent preeclampsia. Most of these trials and later systematic reviews yielded negative results. However, these trials had several important limitations associated with heterogeneity and other issues. Recent research suggests that preeclampsia trials should take into consideration the gender of the fetus (and thus sexual dimorphism of placenta), the positive effect of smoking on preeclampsia prevalence, and the possibility that high doses of LCPUFA mid-term or later may promote the disorder instead of keeping it at bay. In this review, we discuss these issues and future prospects for LCPUFA in
Ключевые слова:
Docosohexaenoic acid; Preeclampsia; Pregnancy; Supplementation
carbon monoxide; docosahexaenoic acid; endoglin; endothelin; fibronectin; heme oxygenase 1; hydroxyprogesterone caproate; icosapentaenoic acid; linoleic acid; messenger RNA; omega 3 fatty acid; phospholipid; soluble fms like tyrosine kinase 1; thrombomodulin; unclassified drug; vasculotropin receptor 1; omega 3 fatty acid; concentration (parameters); cytotrophoblast; diet supplementation; gender; gene overexpression; human; oxidative stress; placenta; preeclampsia; pregnancy; protein expression; randomized controlled trial (topic); Review; smoking; blood; drug effect; female; meta analysis (topic); observational study; physiology; preeclampsia; Fatty Acids, Omega-3; Female; Humans; Meta-Analysis as Topic; Observational Studies as Topic; Placenta; Pre-Eclampsia; Pregnancy; Randomized Controlled Trials as Topic
Язык текста: Английский
ISSN: 2072-6643
Burchakov D. I. Denis Igorevich 1985-
Kuznetsova I. V. Irina Vsevolodovna 1961-
Uspenskaya Yu. B. Yuliya Borisovna 1975-
Бурчаков Д. И. Денис Игоревич 1985-
Кузнецова И. В. Ирина Всеволодовна 1961-
Успенская Ю. Б. Юлия Борисовна 1975-
Omega-3 long-chain polyunsaturated fatty acids and preeclampsia: Trials say “No,” but is it the final word?
Текст визуальный непосредственный
Nutrients
Vol.9, Issue12 Num.1364
2017
Обзор
Docosohexaenoic acid Preeclampsia Pregnancy Supplementation
carbon monoxide docosahexaenoic acid endoglin endothelin fibronectin heme oxygenase 1 hydroxyprogesterone caproate icosapentaenoic acid linoleic acid messenger RNA omega 3 fatty acid phospholipid soluble fms like tyrosine kinase 1 thrombomodulin unclassified drug vasculotropin receptor 1 omega 3 fatty acid concentration (parameters) cytotrophoblast diet supplementation gender gene overexpression human oxidative stress placenta preeclampsia pregnancy protein expression randomized controlled trial (topic) Review smoking blood drug effect female meta analysis (topic) observational study physiology preeclampsia Fatty Acids, Omega-3 Female Humans Meta-Analysis as Topic Observational Studies as Topic Placenta Pre-Eclampsia Pregnancy Randomized Controlled Trials as Topic
Preeclampsia is a dangerous disorder of pregnancy, defined as hypertension with proteinuria. Its nature remains elusive, and measures of prevention and treatment are limited. Observational studies have suggested that preeclampsia is associated with low intake of omega-3 long-chain polyunsaturated fatty acids (LCPUFA). In recent decades, researchers studied LCPUFA supplementation as a measure to prevent preeclampsia. Most of these trials and later systematic reviews yielded negative results. However, these trials had several important limitations associated with heterogeneity and other issues. Recent research suggests that preeclampsia trials should take into consideration the gender of the fetus (and thus sexual dimorphism of placenta), the positive effect of smoking on preeclampsia prevalence, and the possibility that high doses of LCPUFA mid-term or later may promote the disorder instead of keeping it at bay. In this review, we discuss these issues and future prospects for LCPUFA in